Alain Algazi

MD

Medical oncologist
Immunologist, father and rather slow endurance athlete

About me

Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.

In research, Algazi conducts clinical trials – studies that evaluate new therapies for head and neck cancers with an emphasis on approaches to improving the chances of long term remission in patients with incurable cancer using immunotherapy. He has also served the national study chair for clinical trials that give patients access to new medications and that provide new approaches of administering existing medications to improve their efficacy.

Algazi earned his medical degree from the David Geffen School of Medicine at UCLA and completed a residency in internal medicine at Ronald Reagan UCLA Medical Center. He completed a fellowship in hematology-oncology at UCSF.

Algazi is a member of the American Society of Clinical Oncology, Society for Immunotherapy for Cancer and American Association for Cancer Research.

  • Education

    UCLA School of Medicine, 2004

  • Residencies

    UCLA Medical Center, Internal Medicine, 2007

  • Fellowship

    UCSF, Hematology-Oncology, 2010

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

There is a cure for every cancer. Our job is to find it.
Decorative Caduceus

Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated ...

To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgi...

Recruiting

Decorative Caduceus

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.

Recruiting

Decorative Caduceus

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head...

The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free foll...

Recruiting

Share